Radnostix Inc

RADNOSTIX INC is part of a U.S.-based nuclear medicine and isotope business that manufactures calibration and reference standards, radiochemical products, and cobalt-based source products. Its operations span medical, industrial, and research applications, with products distributed in the United States and internationally through company facilities and subsidiaries.

−4,2 %

58,9 %

−6,9 %

−6,0 %

1.16

0.94

— Radnostix Inc
%
Theranostics Products45% Radiopharmaceuticals, APIs, and radiochemicals used in medical, industrial, and research settings.
Cobalt Products25% Bulk cobalt-60, sealed sources, capsule fabrication, and source recycling services.
Nuclear Medicine Standards20% Calibration and reference standards and related quality-control products for imaging workflows.
Molecular Imaging Devices10% Quality-control and calibration devices sold through RadQual and related channels.

Customers include medical device makers, radiopharmaceutical developers, hospitals and imaging centers, and research...

  • Radiopharmaceutical developersprimary

    Buy isotopically pure radiopharmaceuticals, APIs, and radiochemicals for therapy and imaging products.

  • Medical imaging and nuclear medicine usersprimary

    Buy calibration and reference standards plus QC devices to validate imaging systems and workflows.

  • Radiation therapy and industrial source userssecondary

    Buy cobalt-60 products and sealed sources for therapy, industrial, and medical applications.

  • Research and clinical trial organizationssecondary

    Buy radioisotopes for clinical trials and research programs that later feed approved products.

The company is based in the United States and can ship products to all 50 states, while also serving international...

  • United States is the core operating and sales base
  • Products can be shipped to all 50 states
  • International sales support radiochemical and isotope demand
  • U.S. reactor and DOE-linked supply chain is operationally critical
  • China joint venture adds an overseas theranostics footprint

The company is focused on specialized isotope and cobalt products where regulatory capability, licensing, and supply...

01
Strengthen theranostics and radiochemical offeringsmedium-term

These products sit in a growing medical isotope market and require specialized capabilities.

02
Protect isotope supply continuityshort-term

The business depends on just-in-time radioisotope inputs that cannot be stockpiled easily.

03
Defend niche domestic manufacturing positionsmedium-term

Domestic production and unique licensing can differentiate the company from foreign suppliers.

The business is exposed to supply-chain disruption because radioisotopes are sourced through specialized reactors and...

high

Radioisotope supply interruption

The company relies on just-in-time inputs from specialized reactors and suppliers.

Scope
Theranostics Products, Cobalt Products, Calibration & Reference Products
Materiality
high
high

Regulatory and licensing dependence

Operations depend on NRC, FDA, DOE, and transport approvals for production and shipment.

Scope
All isotope-related segments
Materiality
high
medium

Distributor and channel disruption

Loss of territorial distributors could reduce access to end customers.

Scope
International and regional sales
Materiality
medium
medium

Input cost inflation

Raw materials, utilities, energy, and infrastructure costs are not fully controllable.

Scope
Manufacturing and logistics
Materiality
medium
Revenue timing for specialized product shipments
Affects reported sales and comparability across periods
Fluorine Products asset sale accounting
Can materially affect income statement and balance sheet
Promissory note and accrued interest accounting
Affects debt balance and interest expense
Impairment and disposal of specialized assets
Could trigger write-downs or gains/losses on sale

: 29.4.2026